CS Genetics and ROSALIND® Team Up to Advance Genomics
CS Genetics and ROSALIND® Team Up to Advance Genomics
Life Science Innovators Partner to Transform the Samples-to-Insight Cycle
CS Genetics, an innovative genomics technology company, has announced a strategic partnership with ROSALIND®, a premier SaaS platform that empowers life science research. By combining the wet-bench simplicity of CS Genetics' SimpleCell™ platform with ROSALIND®'s multi-omics analysis, this collaboration aims to dramatically enhance researchers' single-cell capabilities.
The integrated solution promises to unlock insights more rapidly and efficiently, allowing scientists to achieve breakthrough discoveries at a significantly lower cost than traditional methodologies.
“At CS Genetics, we've created the SimpleCell™ platform to redefine the economics of single-cell genomics, making it possible to eliminate the need for expensive instruments and greatly reduce per-sample costs,” stated Jay Harger, Chief Operating Officer at CS Genetics. “Our partnership with ROSALIND® enables biopharma and academic teams to undertake larger, more rigorous single-cell projects while gaining access to best-in-class analysis and collaborative tools.”
This unique instrument-free platform is powered by Kinetic Confinement, which simplifies and scales the research process. It integrates seamlessly into established lab workflows, enabling both biopharma and academic researchers to conduct extensive single-cell studies, generating critical insights with remarkable speed.
Tim Wesselman, ROSALIND® Chief Executive Officer, expressed enthusiasm for the collaboration: “We're excited to partner with CS Genetics as they address key barriers to single-cell adoption: complexity and cost. SimpleCell™ allows teams to scale their single-cell research like never before, while ROSALIND® delivers analytical power to quickly interpret and leverage those insights. Together, our aim is to not only accelerate science but also maximize ROI by enabling more projects and empowering larger scientific teams.”
This commitment aims to democratize single-cell genomics, making cutting-edge technology accessible to more biopharma companies and academic labs, thereby enhancing scientific collaboration and discovery.
About CS Genetics
CS Genetics is a privately held genomics-technology company headquartered in Cambridge, UK, and San Diego, California. The company has developed an innovative, instrument-free platform for single-cell genomics, offering disruptive simplicity, speed, and scalability to usher in a new era of next-generation sequencing-based cellular analysis. Its technology employs a molecular process known as Kinetic Confinement, setting it apart from other single-cell technologies and facilitating smooth integration into standard laboratory infrastructures. CS Genetics holds a robust global intellectual property portfolio, covering its single-cell platform, related reagents, workflow methodologies, manufacturing techniques, and application technologies.
About ROSALIND®
ROSALIND is a cutting-edge cloud-based SaaS platform designed to empower life science researchers in analyzing, interpreting, and collaborating on multi-omic data seamlessly—without the need for coding. The platform enhances research processes from data integration to the extraction of actionable insights. By fostering collaboration across various teams and technologies, ROSALIND expedites discoveries in biopharma, academia, and clinical research, recognizing that a unified platform is essential to unlock biological secrets. The company continues to lead innovation in gene expression, single-cell, and spatial biology research.
Contact Information
Shannon Wilsey | CS Genetics PR
For inquiries, please reach out via email.
Frequently Asked Questions
What is the significance of the partnership between CS Genetics and ROSALIND®?
This partnership aims to enhance single-cell genomics capabilities, making advanced technology more accessible for researchers in the life sciences.
What are the key technologies involved in this collaboration?
The partnership combines the SimpleCell™ platform from CS Genetics with the analytical power of ROSALIND®, aimed at simplifying workflow and reducing costs in single-cell research.
How does the SimpleCell™ platform impact research?
SimpleCell™ is designed to eliminate the need for complex and expensive instruments, allowing researchers to conduct larger projects with reduced costs.
Who are the main beneficiaries of this technology?
The technology benefits biopharma teams and academic researchers by providing them with tools for extensive single-cell studies and data analysis.
What future developments can we expect from this partnership?
Future developments may include more integrated solutions that enhance collaboration and insights generation across disciplines in the life sciences.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.